Why Is SELLAS LIFE SCIENCES (SLS) Stock Up Today?

Sellas Life Sciences (SLS) shares rose 6.85% to $8.58, driven by anticipation of pivotal Phase 3 trial results for its acute myeloid leukemia therapy. The company confirmed that its GPS study has reached the 80th required event, with final data expected to be released this month.

What Happened

Sellas Life Sciences reported third-quarter financial results that met analyst expectations, with a GAAP loss per share of $0.05. The company disclosed that it held approximately $134.7 million in cash and cash equivalents as of September 30, 2026. Although the net loss widened to $10.1 million for the quarter, the per-share loss narrowed compared to the prior year. The stock initially gapped up 18.8% to open at $9.54, a significant move from the previous close of $8.03. This surge followed reports that the company described the upcoming Phase 3 results as transformative. The company filed a Form 8-K with the SEC on November 12, 2026, to disclose these operational results and financial statements.

What The Data Shows

The intraday session showed volatility as the stock peaked at $9.81 at 7:00 AM ET before pulling back to a session low of $8.36 at 8:25 AM ET. Trading volume reached 1.1 million shares, which is 0.2 times the three-month daily average. The stock has a high beta of 2.70 and remains unprofitable with a trailing twelve-month EPS of -$0.21. Its market capitalization stands at $1.7 billion. Over the last eight sessions, the stock had declined 9.5% from $8.87 to $8.03 before the recent jump. The 52-week range for the stock is $1.39 to $15.88. On November 13, 2026, the stock printed both a fresh 52-week high and a fresh 52-week low.

What To Watch

Investors are focused on the release of the pivotal GPS trial results, which are scheduled for this month. The market will assess how the final data impacts the company's valuation and its path toward profitability.